

Our 2022 Report

Janssen

£130,000 went towards supporting the <u>Covid-19 Vaccine Research</u> <u>Collaborative</u>. Another £37,000 went towards research undertaken by UCL in order to reduce <u>delays to diagnosis of blood cancer</u>.

Gilead

£300,000 went towards supporting the <u>Covid-19 Vaccine Research</u> Collaborative.

Pfizer

Pfizer gave £130,176 towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic.

Novartis

£80,000 went towards supporting our <u>Clinical Trials Support Service</u>. We also received £15,000 from Novartis which was redirected to the Blood Cancer Alliance for their membership.

Takeda

£100,000 went towards supporting the <u>Covid-19 Vaccine Research</u> <u>Collaborative</u>. Another £60,000 went towards supporting our <u>Clinical Trials Support Service</u>.

Bristol Myers Squibb

£230,000 went towards supporting the <u>Covid-19 Vaccine Research</u> <u>Collaborative</u>. Another £60,000 went towards supporting our <u>Clinical Trials Support Service</u>.

AbbVie

AbbVie gave £12,000 for our befriending service.

Roche

£100,000 went towards supporting the <u>Covid-19 Vaccine Research</u> Collaborative.



Jazz

Jazz gave £10,000 to support our health information project and £10,000 towards a project supporting marginalised communities.

Incyte

Incyte gave £15,000 to support our health information project.

AstraZeneca

AstraZeneca paid Blood Cancer UK £308 for our participation in an advisory board.

Kyowa Kirin

£5,000 went towards a project supporting marginalised communities.

Autolus

Autolus gave £75,000 to support our Clinical Trials Support Service.

GSK

£10,000 went towards a project supporting marginalised communities.

UCB Pharma

£1,000 went towards our support services.